Genes conferring resistance to anticancer drugs can be transferred to and expressed in hematopoietic cells to prevent the myelotoxicity of cancer chemotherapy and to select gene-modified cells in vivo. In oncology, this approach is of particular interest to enable intensified consolidation chemotherapy after autologous or allogeneic transplantation of hematopoietic progenitor cells. We have developed retroviral vectors that mediate strong expression of chemoresistance-mediating genes in early human hematopoietic cells and their progeny. This was achieved by defining appropriate cis-acting elements for initiation of transcription and by improving post-transcriptional processing of vector-RNA. In murine models of marrow transplantation conditions were investigated that influence the outcome of in-vivo-selection. Studies were performed with retroviral vectors encoding the human multi-drug-resistance 1 (MDT1) gene alone or in combination with O6-alkylguanidine-alkyltransferase, which extends the resistance of transduced cells to nitrosureas. The data indicate that post-transplantation chemotherapy is feasible when expressing resistance genes to dominant levels in repopulating hematopoietic cells. Important determinants of reliable chemoprotection and selection of transduced cells in vivo are the design of the retroviral vector as well as the type and dosage of the chemotherapeutic agents. Clinical studies with improved chemoresistance-mediating vectors are in preparation. substances. Experiments were performed with primary murine bone marrow cells using an N2/Zip based retroviral vector expressing MGMT from the human phosphoglycerokinase promotor. While LD50 in clonogenic progenitors for BCNU was 45.9 Ϯ 24.1 M in MGMT transduced cells versus 14.0 Ϯ 3.2 M in mock transduced controls (average increase 3.1 Ϯ 1.1; n = 3), data for CCNU were 2.1 Ϯ 0.8 g/ml versus 0.4 Ϯ 0.3 g/ml (average increase 6.4 Ϯ 2.8; n = 3), for ACNU 10.54 Ϯ 5.4 g/ml versus 2.58 Ϯ 1.7 g/ml (average increase 7.24 Ϯ 9.3; n = 6) and for Temozolomide 159.7 Ϯ 52.2 g/ml versus 99.8 Ϯ 27.8 g/ml (average increase 1.49 Ϯ 0.29; n = 3). Transduction efficency was 70-100% as shown by single colony PCR. To improve on these results we have constructed and currently investigate new retroviral vectors using backbones such as MSCV (based on Myeloproliferative Surcoma Virus, MPSV) or SF1 which combines MSCV leader sequences and Spleen Focus Forming Virus (SFFV) derived LTR sequences. Transduktion with these vectors rendered human clonogenic cells resistent to ACNU concentrations of 2 to 16 g/ml. Protection was better with vectors expressing MGMT alone in comparison to "multigene"-vectors.
Genes conferring resistance to anticancer drugs can be transferred to and expressed in hematopoietic cells to prevent the myelotoxicity of cancer chemotherapy and to select gene-modified cells in vivo. In oncology, this approach is of particular interest to enable intensified consolidation chemotherapy after autologous or allogeneic transplantation of hematopoietic progenitor cells. We have developed retroviral vectors that mediate strong expression of chemoresistance-mediating genes in early human hematopoietic cells and their progeny. This was achieved by defining appropriate cis-acting elements for initiation of transcription and by improving post-transcriptional processing of vector-RNA. In murine models of marrow transplantation conditions were investigated that influence the outcome of in-vivo-selection. Studies were performed with retroviral vectors encoding the human multi-drug-resistance 1 (MDT1) gene alone or in combination with O6-alkylguanidine-alkyltransferase, which extends the resistance of transduced cells to nitrosureas. The data indicate that post-transplantation chemotherapy is feasible when expressing resistance genes to dominant levels in repopulating hematopoietic cells. Important determinants of reliable chemoprotection and selection of transduced cells in vivo are the design of the retroviral vector as well as the type and dosage of the chemotherapeutic agents. Clinical studies with improved chemoresistance-mediating vectors are in preparation. .1 Ϯ 1.1; n = 3), data for CCNU were 2.1 Ϯ 0.8 g/ml versus 0.4 Ϯ 0.3 g/ml (average increase 6.4 Ϯ 2.8; n = 3), for ACNU 10.54 Ϯ 5.4 g/ml versus 2.58 Ϯ 1.7 g/ml (average increase 7.24 Ϯ 9.3; n = 6) and for Temozolomide 159.7 Ϯ 52.2 g/ml versus 99.8 Ϯ 27.8 g/ml (average increase 1.49 Ϯ 0.29; n = 3). Transduction efficency was 70-100% as shown by single colony PCR. To improve on these results we have constructed and currently investigate new retroviral vectors using backbones such as MSCV (based on Myeloproliferative Surcoma Virus, MPSV) or SF1 which combines MSCV leader sequences and Spleen Focus Forming Virus (SFFV) derived LTR sequences. Transduktion with these vectors rendered human clonogenic cells resistent to ACNU concentrations of 2 to 16 g/ml. Protection was better with vectors expressing MGMT alone in comparison to "multigene"-vectors. It has been clearly demonstrated in murine systems that transfection of tumor cells with these molecules augments immunogenicity, resulting in the recruitment of immune effector cells and eradication of a tumor cell challenge. For many solid tumors cytokine gene transfer seems to be an efficient approach, while for generation of an anti-leukemia response costimulatory surface molecules or combinations of immunostimulatory signals acting on different levels of the immune response seem to be advantageous. Here we demonstrate that combining IL-2 with either the T-cell specific chemokine lymphotactin or the costimulatory molecule CD40 ligand significantly enhances the anti-leukemia response in a murine leukemia model. We also show that this combinatory vaccine approach eradicates established leukemic disease. In addition, cytokines and costimuatory surface molecules may be effectively delivered by subpopulations of transfected tumour cells or bystander cells such as fibroblasts. These data demonstrate that a high concentration of these mediators at the vaccine site is crucial, irrespective of the cellular source and that the logistic demands of cultivating primary human leukemia cells may be circumvented by this approach. When utilizing peptide-pulsed dendritic cells in conjunction with CD40L/IL-2 costimulation, mice were proteced from leukemic disease, however, developed an autoimmune-like response. Future studies aim to minimize the auto-immune effects while maintaining efficacy of the anti-neoplastic response. We here report our progress in establishing appropriate techniques and protocols as part of the preclinical service for two different gene therapy trials including CD34
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+ and T-cell transduction. Using our high titer producer cell clones and optimized parameters for vector production from cell factories (NUNC) we routinely generate serumfree retroviral supernatant with sufficient quality (i.e. Ͼ10 6 infectious particles/ml from frozen samples). We have modified existing transduction protocols for CD34 + and Tcells particularly with respect to cell concentration. These modifications enable us to achieve transduction efficiencies of 60-70% with cell numbers in the range of a whole transplant (Ͼ10 8 cells). Analysis of the genetically modified human hematopoietic progenitor/stem cells in NOD/SCID mice show repopulation from the transduced cell fraction. FACS analysis and a highly specific quantitative PCR assay detect between 10-20% transgene positive human cells 6 weeks after transplantation.
These data together with production procedures in compliance with GMP guidelines complete the prerequisites necessary for state of the art performance of clinical gene therapy trials.
